Tag: GlobeNewswire

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Gamma Communications plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	02/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.25p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	761,936	0.85
(2) Cash-settled derivatives:	399,984	0.44
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	1,161,920	1.30

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.25p ordinary	Equity swap	Reducing a long position	21,738	10.9685 GBP
0.25p ordinary	Equity swap	Reducing a long position	41	10.9835 GBP
0.25p ordinary	Equity swap	Reducing a long position	61	10.9835 GBP
0.25p ordinary	Equity swap	Increasing a long position	1,157	10.9273 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	03/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

#FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Rotork Plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	02/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	0.5p ordinary
	Interests		Short positions
	Number	%		Number	%
(1) Relevant securities owned and/or controlled:
(2) Cash-settled derivatives:	16,393,523	2.00		11,213	0.00
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	16,393,523	2.00		11,213	0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
0.5p ordinary	Equity Swap	Reducing a long position	2,725	4.9318 GBP
0.5p ordinary	Equity Swap	Reducing a long position	1,753	4.9330 GBP
0.5p ordinary	Equity Swap	Reducing a long position	1,279	4.9325 GBP
0.5p ordinary	Equity Swap	Increasing a long position	3,160	4.9300 GBP
0.5p ordinary	Equity Swap	Increasing a long position	739	4.9300 GBP
0.5p ordinary	Equity Swap	Increasing a long position	42,289	4.9300 GBP
0.5p ordinary	Equity Swap	Increasing a long position	15,965	4.9362 GBP
0.5p ordinary	Equity Swap	Increasing a long position	984	4.9300 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	03/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Spire Healthcare Group plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	02/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:
(2) Cash-settled derivatives:	6,268,512	1.55
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	6,268,512	1.55

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	Equity swap	Increasing a long position	7,566	2.4890 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	03/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Sthree plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	02/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	NO

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	1p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	6,943,299	5.71
(2) Cash-settled derivatives:	3,433,624	2.82	15,497	0.01
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	10,376,923	8.54	15,497	0.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
1p ordinary	Equity swap	Reducing a long position	284	3.0406 GBP
1p ordinary	Equity swap	Reducing a long position	4,962	3.0819 GBP
1p ordinary	Equity swap	Reducing a long position	1,089	3.0881 GBP
1p ordinary	Equity swap	Reducing a long position	755	3.0406 GBP
1p ordinary	Equity swap	Reducing a long position	16,142	3.0819 GBP
1p ordinary	Equity swap	Reducing a long position	3,543	3.0881 GBP
1p ordinary	Equity swap	Reducing a long position	13	3.0406 GBP
1p ordinary	Equity swap	Reducing a long position	80	3.0819 GBP
1p ordinary	Equity swap	Reducing a long position	17	3.0881 GBP
1p ordinary	Equity swap	Reducing a long position	1,862	3.0406 GBP
1p ordinary	Equity swap	Reducing a long position	1,249	3.0467 GBP
1p ordinary	Equity swap	Reducing a long position	30,761	3.0819 GBP
1p ordinary	Equity swap	Reducing a long position	6,753	3.0881 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	03/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Consumer research highlights how postpartum, perimenopause and menopause can bring overlapping protection needs

Aalst, Belgium, November 3, 2026 – Ontex is expanding its multi-liquid protection range with adult pants designed to support women whose protection needs can change and overlap through different life stages. Building on its expertise in feminine and adult care, Ontex is developing solutions for diverse needs including bladder leaks, menstrual flow, discharge and sweat.

Ontex’s research highlighted pregnancy and menopause as important moments in women’s experience of incontinence. The study found that 78% of respondents reported a bladder-related change during perimenopause or menopause. It also shows how protection needs can overlap: 54% of women using absorbent protection experience more than one need at the same time, while 62% see strong value in a product designed to manage different types of moisture or discharge.

“Women’s needs do not suddenly move from one category to another as their bodies change. Following childbirth and during perimenopause and menopause, bladder leaks can overlap with other protection needs,” says Tatiana Bumachar Carvalho Pastori, Category Lead Adult Care at Ontex. “By bringing together our expertise in feminine and adult care, we can develop practical solutions that support women as their bodies and protection needs evolve.”

From consumer insight to multi-liquid protection
Multi-liquid protection is designed to help manage different types of moisture within one product, rather than treating women’s needs as separate categories.

Ontex launched its multi-liquid liner earlier this year and is now expanding the offer with pants, newly qualified for multi-liquid protection needs during postpartum and perimenopause. Multi-liquid pads are planned to follow, creating a broader portfolio that retailers across Europe can introduce under their own brands.

Featuring Ontex’s patented X-Core channel technology, the pants combine an underwear-like fit with a thin and flexible absorbent core, softness, breathability, leak protection and odour control.

Making multi-liquid protection more accessible
Price matters too. In the Vypr study, 44% of women identified affordability as an important product feature, alongside comfort (51%) and odour control (45%). The study also found that 41% had changed their buying behaviour because of cost.

By working with retailers on their own-brand ranges, Ontex aims to make multi-liquid protection available to more women at an accessible price point.

“Innovation starts by understanding the real needs consumers face, rather than the traditional categories they shop in”, says Lilian Girlea, President Europe. “By combining our expertise in feminine and adult care with our technology platforms and close collaboration with retailers, we can translate these insights into relevant, high-quality and accessible solutions for women across different life stages.”

About the research

• Dynata: research conducted in 2025 among 2,500 respondents in the UK and Germany, covering users and carers.
• Vypr: research conducted through Vypr Predict in the UK in September 2026 among approximately 490 women aged 45+ experiencing perimenopause or menopause; sample size varies by question.

For images, please check our Media download center.

Enquiries

Media	Catherine Weyne	+32 53 333 622	corporate.communications@ontexglobal.com
Investors	Geoffroy Raskin	+32 53 333 730	investor.relations@ontexglobal.com

About Ontex

Ontex is a leading international developer and producer of baby care, feminine care and adult care products, both for retailers and healthcare, primarily in Europe and North America. The group employs around 5,000 people, with plants and offices in 12 countries, and its innovative products are distributed in around 100 countries. Ontex is headquartered in Aalst, Belgium and is listed on Euronext Brussel, where it is a constituent of the Bel Mid^® index. To keep up with the latest news, visit ontex.com or follow Ontex on LinkedIn.

ONTEX Group NV
Korte Keppestraat 21 – 9320 Erembodegem (Aalst) – Belgium                                                      0550.880.915 RPR Ghent – Division Dendermonde

Attachment

• 261103_PR_Ontex multi-liquid pants_EN

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:	Man Group PLC
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):  The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
(c) Name of offeror/offeree in relation to whose relevant securities this form relates:  Use a separate form for each offeror/offeree	Vesuvius plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:
(e) Date position held/dealing undertaken:  For an opening position disclosure, state the latest practicable date prior to the disclosure	02/11/2026
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?	YES Offeror: RHI Magnestia N.V.

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:	10p ordinary
	Interests		Short positions
	Number	%	Number	%
(1) Relevant securities owned and/or controlled:	13,143,478	5.29
(2) Cash-settled derivatives:	250,700	0.10	451,824	0.18
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:
TOTAL:	13,394,178	5.39	451,824	0.18

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

(b) Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
10p ordinary	Equity Swap	Reducing a long position	5,709	4.7505 GBP
10p ordinary	Equity Swap	Reducing a long position	16,222	4.7505 GBP
10p ordinary	Equity Swap	Reducing a short position	500	4.7511 GBP
10p ordinary	Equity Swap	Reducing a long position	87	4.7505 GBP
10p ordinary	Equity Swap	Reducing a short position	20,300	4.7511 GBP
10p ordinary	Equity Swap	Reducing a short position	22,100	4.7511 GBP
10p ordinary	Equity Swap	Reducing a short position	1,400	4.7511 GBP
10p ordinary	Equity Swap	Reducing a short position	3,100	4.7511 GBP
10p ordinary	Equity Swap	Reducing a long position	37,784	4.7505 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to: (i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

NO

Date of disclosure:	03/11/2026
Contact name:	Molly Childs
Telephone number:	+44 20 7144 3714

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

  

• Global Enterprise: Complementary portfolios and geographic strengths create a truly global enterprise, with presence in over 130 countries across key developed and high-growth markets in Europe, India, South America, Asia, the Middle East and Africa, and combined revenues of ~€21 billion (INR 2,28,000 Cr.+)
• Worldwide Footprint: 27 manufacturing sites and 25 R&D centres, supported by a network of over 9,300 sales and service centres
• Customer First: Combining global capabilities with deep local understanding to deliver greater value and excellence for customers
• Talent Power: 73,000+ employees across six continents, creating a formidable global talent and technology base to define the future of commercial mobility
• Proudly Distinct: Preserving the strength of our brands, identities and industrial foundations, while exploring newer opportunities for growth
• Seamless Continuity: Customers, dealers, suppliers and partners experience seamless continuity from day one
• Possibilities Multiplied: New opportunities to unlock technology, market access and scale, with capabilities flowing both ways

Mumbai and Turin, 3 November 2026: Tata Motors Limited, India’s largest commercial vehicle manufacturer, and Iveco Group N.V., a leading international player in commercial vehicles, buses and powertrains, today marked a new beginning together as a global commercial mobility enterprise with the scale, reach and capabilities to compete and grow across markets and technology cycles. Ranked fourth¹ in the world amongst commercial vehicle manufacturers, the new enterprise combines deep industrial heritage, strong brands and complementary product portfolios spanning the breadth of commercial mobility, with a strategically diversified and growing presence across Europe, India, South America, Asia, the Middle East and Africa.

Announcing this at a global press meet in Turin, Italy, Mr. N Chandrasekaran, Chairman, Tata Sons, Tata Motors and Iveco Group, said: Today marks the beginning of an exciting new chapter for Tata Motors and Iveco Group. Two strong and successful organisations, united by shared values, a common commitment to sustainable mobility and an ambition to shape the future of commercial transportation, have come together to create a truly global commercial mobility enterprise. We will invest for the long term, enable ideas and capabilities to flow in both directions, and harness our combined scale, reach and talent to shape a future of mobility that is safer, smarter, more connected and more sustainable. I take this opportunity to express my appreciation to the Italian Government, the regulatory authorities across jurisdictions, our employees, shareholders and all the stakeholders whose trust, cooperation and support have helped us reach this important milestone. I also warmly welcome our colleagues from Iveco Group into the Tata family and look forward to all that we can achieve together.”

The collective strength and expertise of Tata Motors and Iveco Group in advanced powertrains, alternative energy, software, connected technologies and manufacturing, will accelerate innovation, open new frontiers for growth, and bring cleaner, smarter mobility solutions to customers at greater speed and scale, helping shape the future of commercial mobility.

Speaking on the occasion, Mr. Girish Wagh, MD & CEO, Tata Motors, said: “We are pleased to turn our strategic vision into an operational reality alongside our colleagues at Iveco Group. Together we have a compelling opportunity to create greater value for our customers and stakeholders. Our complementary portfolios, capabilities and geographic strengths provide a strong foundation for growth, while ensuring continuity from day one for customers, dealers and partners. Our ambition is to build a stronger enterprise by combining our strengths in engineering, new age technologies, sourcing, distribution and customer networks. We will accelerate innovation, broaden our reach and bring advanced solutions to customers faster and more competitively.”

United by a shared ambition for growth and green mobility, Tata Motors and Iveco Group will harness their combined scale, the talent of over 73,000 people and a two-way flow of engineering, technology and expertise to unlock the full potential of the combination.

Commenting on this fundamental milestone, Mr. Olof Persson, Chief Executive Officer, Iveco Group, said: “This is a defining moment for Iveco Group, and one we approach with confidence and great energy. We begin this new chapter proudly, with the brands, people, capabilities and industrial heritage that have shaped our company, alongside Tata Motors, a partner of great strength, with a deep understanding of the commercial vehicle business and a shared long-term perspective and commitment to sustainable transport. I want to thank our employees, customers, dealers, suppliers and partners for their trust and support. We now have the opportunity to build on everything Iveco Group has achieved, unlock new possibilities with Tata Motors and create an even stronger future.”

ANNEXURE

Strong Identities. Shared Ambition. Built for the Future.
The combination is founded on a clear principle: build on what makes Tata Motors and Iveco Group individually strong, while unlocking the greater possibilities they can create together.

Iveco Group will remain headquartered in Turin, Italy, with its brands, teams and industrial footprint retaining their distinct identities. Tata Motors will support Iveco Group’s existing strategy and investment plans, while both organisations collaborate to leverage their complementary strengths, deepen capabilities and create greater value for customers and stakeholders.

Global Scale. Worldwide Reach.
Together, Tata Motors and Iveco Group form a commercial mobility enterprise of significant global scale, with a presence in over 130 countries, sales volumes of ~590,000 units and combined revenues of ~€21 billion (INR 2,28,000 Cr.+).
This worldwide presence is supported by a strong industrial, innovation and customer network: 27 manufacturing sites, 25 R&D centres and approximately 9,300 sales and service centres.

Powering Mobility. Today and Tomorrow.
Across the combined enterprise, powertrain capabilities span the full spectrum: from conventional and established combustion technologies to natural gas to battery-electric, hydrogen and other emerging zero- and low-emission solutions.
This breadth of technologies, fuel choices and applications creates a powerful foundation to pursue multiple pathways to decarbonisation, addressing different customer needs and market realities while accelerating the transition towards cleaner commercial mobility.

For Customers. For Growth. For the Future.
The power of the combination lies in complementarity.

Tata Motors’ commercial vehicle portfolio spans sub-1-tonne to 55-tonne cargo vehicles and 10-seater to 51-seater mass-mobility solutions, with deep capabilities in India and high-growth emerging markets of Asia, Middle East & North Africa.

Iveco Group brings extensive capabilities across light, medium and heavy commercial vehicles and city and intercity buses, with strong positions across Europe and Latin America. FPT adds significant powertrain capabilities across on-road, off-road, marine and power-generation applications.

Together, this means more choice for customers: a broader range of vehicles, technologies and powertrain solutions, backed by the capabilities and reach to address increasingly diverse mobility needs.

Together, these strengths also create new possibilities to develop and deploy the next generation of commercial mobility solutions. Greater scale will help bring innovation to market faster and more competitively, while building on the distinct operational strengths of both organisations giving customers access to stronger technologies, capabilities, solutions and market reach across the combined enterprise. Importantly, the growth opportunity extends beyond Tata Motors and Iveco Group. It creates a larger canvas for ecosystem partners – suppliers, dealers and distributors – to grow with the combined enterprise, access new markets and opportunities, and collectively deliver greater value to customers around the world.

73,000+ people. A larger world of opportunity.
At the heart of this new global enterprise are more than 73,000 people across Tata Motors and Iveco Group, bringing together deep experience, diverse perspectives and world-class capabilities.
For employees, the combination opens new opportunities for collaboration, learning and professional growth. Technology, engineering expertise, market knowledge and best practices will flow in both directions, enabling both teams to learn from each other, innovate faster and take proven solutions and capabilities to more customers and markets around the world.

Seamless Transition
For customers, dealers, suppliers and business partners, the transition is seamless. Existing customer contracts, dealer and supplier relationships, warranties, aftermarket commitments and captive financing solutions continue unchanged and are supported by the same dedicated teams and networks.

The Road Ahead
With strong roots in India and Europe and a significant presence across Latin America and other international markets, Tata Motors and Iveco Group now move forward with a shared ambition: to create a stronger, more innovative and more resilient commercial mobility enterprise, capable of leading through the profound transformation underway in transportation.
The immediate priority is continuity. The longer-term opportunity is greater: to use the combined strength of the two organisations to accelerate innovation, expand customer choice, create new growth opportunities and advance the transition towards cleaner, safer and more intelligent mobility.

Contacts

Tata Motors Media Contacts

Tata Motors Corporate Communications: cvcomms@tatamotors.com

Iveco Group Media Contacts

Francesco Polsinelli, Tel: +39 335 1776091

Fabio Lepore, Tel: +39 335 7469007

E-mail: mediarelations@ivecogroup.com

Tata Motors Investor Relations

Phone: +91-22-6665-8282

E-mail: investors@tatamotors.com; ir_tml@tatamotors.com

Iveco Group Investor Relations

Federico Donati, Tel: +39 011 0073539

E-mail: investor.relations@ivecogroup.com

About Tata Motors (Formerly TML Commercial Vehicles Ltd):

Part of the USD 180 billion Tata Group, Tata Motors Ltd. (BSE: Scrip code 544569; NSE: Scrip code TMCV) is India’s largest manufacturer of utility vehicles, pick-ups, trucks and buses. Together with its subsidiary Iveco Group N.V., it is a global mobility enterprise with complementary brands, technologies and deep engineering expertise with a presence across 130+ countries and solutions spanning the entire spectrum of commercial mobility. Backed by Tata Motors’ eight decades of leadership, the combined enterprise brings greater scale, technological depth and international reach to serve evolving customer needs and shape the future of mobility. Guided by its brand promise, Better Always, Tata Motors continues to engineer future-ready solutions that enhance customer experience and drive sustainable growth.

As per the Composite Scheme of Arrangement sanctioned by the Hon’ble National Company Law Tribunal, Mumbai Bench—amongst Tata Motors Limited, TML Commercial Vehicles Limited (the Company) and Tata Motors Passenger Vehicles Limited—the Company’s name was changed to Tata Motors Limited from TML Commercial Vehicles Limited (effective 29 October 2025), and its equity shares are listed on the BSE Ltd and the NSE Ltd.

About Iveco Group

Iveco Group N.V. (EXM: IVG), a subsidiary of Tata Motors Ltd. and part of a leading global commercial mobility enterprise, is a major player in the automotive industry, built on a strong Italian heritage and with a consolidated international reach. The Group channels decades of engineering excellence and innovation into sustainable mobility and customer driven technologies. Its five brands play a leading role in their respective domains: IVECO, a pioneering commercial vehicles brand offering heavy, medium and light duty trucks; FPT, a global leader in advanced powertrain technologies in the agriculture, construction, marine, power generation and commercial vehicles sectors; IVECO BUS and HEULIEZ, renowned for their mass transit, premium bus and coach solutions; and IVECO CAPITAL, the Group’s financing arm supporting them all. Iveco Group employs 33,000 people and operates 16 industrial sites and 22 R&D centres. Further information is available at www.ivecogroup.com.

 -ENDS- 

---

1By Truck Sales Volumes in >6 ton segment

Attachment

• 20261103_IVG_PR_Tata_Motors_and_Iveco_Group_combine_scale

FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY
Rule 8.5 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)        Name of exempt principal trader:	Investec Bank Plc
(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offeree	SThree Plc
(c)        Name of the party to the offer with which exempt principal trader is connected:	Investec is Joint Broker to SThree Plc
(d)        Date dealing undertaken:	02nd November 2026
(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer or possible cash offer, state “N/A”	N/A

2.        DEALINGS BY THE EXEMPT PRINCIPAL TRADER

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security	Purchases/ sales	Total number of securities	Highest price per unit paid/received	Lowest price per unit paid/received
Ordinary shares	Purchase	54,859	310	303
Ordinary shares	Sales	54,859	310	303

(b)        Cash-settled derivative transactions

Class of relevant security	Product description e.g. CFD	Nature of dealing e.g. opening/closing a long/short position, increasing/reducing a long/short position	Number of reference securities	Price per unit
N/A	N/A	N/A	N/A	N/A

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security	Product description e.g. call option	Writing, purchasing, selling, varying etc.	Number of securities to which option relates	Exercise price per unit	Type e.g. American, European etc.	Expiry date	Option money paid/ received per unit
N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

(ii)        Exercise

Class of relevant security	Product description e.g. call option	Exercising/ exercised against	Number of securities	Exercise price per unit
N/A	N/A	N/A	N/A	N/A

(d)        Other dealings (including subscribing for new securities)

Class of relevant security	Nature of dealing e.g. subscription, conversion	Details	Price per unit (if applicable)
N/A	N/A	N/A	N/A

3.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer: Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to: (i)        the voting rights of any relevant securities under any option; or (ii)        the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced: If there are no such agreements, arrangements or understandings, state “none”

None

Date of disclosure:	03rd November 2026
Contact name:	Abhishek Gawde
Telephone number:	+91-9923757332

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at ssssssswwww.thetakeoverpanel.org.uk.

MONTREAL, Nov. 03, 2026 (GLOBE NEWSWIRE) — Cerro de Pasco Resources Inc. (TSXV CDPR | OTCQX CDPMF | FRA N8HP | BVL CDPR) (“CDPR” or the “Company”) is pleased to report progress on the Phase 2 drilling campaign at the Quiulacocha tailings storage facility (the “Quiulacocha TSF”) in Cerro de Pasco, Peru. Drilling began on August 25, 2026, and covers 97 locations authorized by the Peruvian National Water Authority (Autoridad Nacional del Agua, “ANA”). Phase 2 follows the 40-hole Phase 1 program completed in 2025, the results of which were reported in the Company’s news release of April 9, 2025. The Phase 2 drilling campaign has been designed to generate the geological, hydrogeological, geotechnical and environmental data for the first Mineral Resource Estimate (“MRE”) for the Quiulacocha tailings and for the Environmental Impact Assessment (“EIA”) of the Quiulacocha tailings reprocessing project (the “Project”). It follows the definitive agreements with Activos Mineros S.A.C. (“AMSAC”) announced on October 21, 2026, which consolidated the Company’s rights over 100% of the Quiulacocha tailings.

Highlights

• Two sonic rigs on site: a compact rig on the dry zone since August 25 and an amphibious heli-sonic rig on the ponded zone since October 1
• 34 holes completed for 1,039 m and 773 samples collected as of November 1, 2026
• 97 drilling locations authorized by ANA: 79 investigation holes and 18 piezometers
• Drilling expected to be completed in Q2 2027 with the first MRE targeted for Q3 2027
• Phase 2 drilling is a defined activity under the US$5 million project development funding agreement with the U.S. International Development Finance Corporation (“DFC”)

Guy Goulet, CEO of Cerro de Pasco Resources, commented:

“Following the consolidation of our rights over 100% of the Quiulacocha tailings, we are advancing the most comprehensive drilling campaign undertaken at the facility to date. With 97 authorized drilling locations and two sonic rigs operating across both the dry and ponded areas, we are building the technical foundation for our first Mineral Resource Estimate, targeted for the third quarter of 2027, and for the technical and permitting studies of the Project. Supported by the U.S. International Development Finance Corporation, this campaign represents another significant milestone in transforming Quiulacocha into a flagship resource recovery and environmental remediation project.”

Drilling Program

Cerro de Pasco Resources del Perú S.A.C. (“CDPR Perú”) contracted ConeTec Perú S.A.C., a subsidiary of the ConeTec Group of Canada, in April 2026, to carry out the Phase 2 program. In June 2026, ANA authorized 97 drilling locations for the investigation of the facility, its hydrogeological study and the environmental baseline of the EIA: 79 investigation holes and 18 Casagrande piezometers, located both within the El Metalurgista concession and in the sector of the Quiulacocha TSF outside the concession, over which the Company holds surface access under its agreements with AMSAC. Together with the 40 holes drilled in Phase 1, the program brings the combined coverage of the Quiulacocha TSF to 116 geological drillholes and 18 piezometers (Figure 1).

The compact sonic rig was mobilized on August 20, 2026, and began drilling on the dry, trafficable zone of the facility on August 25 (Figure 2). The amphibious fleet, comprising a heli-sonic rig, an amphibious platform and an amphibious excavator, was assembled from September 9 and began drilling on the ponded zone on October 1, 2026 (Figure 3). Sonic drilling produces a continuous core through the full tailings column and allows sampling at 1.5-meter intervals. Resource definition holes are drilled to foundation. Geotechnical and hydrogeological holes are drilled by sonic and diamond methods into the underlying sediments and bedrock and include undisturbed Shelby tube samples, seismic cone penetration tests (“SCPTu”), downhole geophysical logging and the installation of standpipe piezometers.

Figure 1. Phase 2 drilling program status

Figure 2. Sonic compact rig on modular drilling platform

Figure 3. Heli-sonic rig mount on amphibious carrier

Progress to Date

As of November 1, 2026, 34 holes had been completed, for a total of 1,039 m drilled. As of the cut-off date, 773 samples had been collected, and a total of seven drillholes had been logged at the Company’s core facility in Ate, Lima. Samples are stored under frozen-transport conditions from field collection to laboratory processing, maintaining chain of custody (Figure 4).

Figure 4. Freezer container with drilling samples

Objectives of the Campaign

The campaign has four objectives:

• Geology and resource definition: define the stratigraphy, thickness and base of the tailings across the facility and complete the drillhole density required for a first MRE under National Instrument 43-101 (“NI 43-101”) and the CIM Definition Standards
• Hydrogeology: characterize groundwater flow, hydraulic connectivity and water quality through hydraulic conductivity testing, downhole geophysics and the 18 piezometers
• Geotechnics: obtain the parameters for the physical stability assessment of the facility from the SCPTu tests and laboratory testing of undisturbed Shelby tube samples
• Environmental baseline: provide the geochemical, hydrogeological and geotechnical information on the tailings and their foundation that the EIA requires

Tailings Beneath the Excelsior Stockpile

Historical data, including a 2009 reverse circulation drilling campaign by Volcan Compañía Minera S.A.A. described in the Company’s NI 43-101 technical report dated March 15, 2021, indicate that part of the Quiulacocha tailings lie beneath the adjacent Excelsior stockpile (Figure 5). The Company is evaluating a drilling program at the toe of the stockpile to define the geology, geotechnics and hydrogeology of that portion of the tailings, subject to surface access and required permits. No mineral resource has been established for the tailings beneath the stockpile.

Figure 5. Quiulacocha and Excelsior outlines overlayed on the Aerial Photograph from 1963

Support from the U.S. International Development Finance Corporation

As announced on March 2, 2026, the Company entered into a Project Development Funding Agreement with DFC under which DFC will provide up to US$5 million in milestone-based project development funding to support defined project development activities for the Quiulacocha Tailings Reprocessing Project. The defined activities include sonic drilling, geotechnical and hydrogeological drilling, completion of a Feasibility Study and Engineering program and preparation of a comprehensive Environmental and Social Impact Assessment, with CDPR contributing matching funds for the applicable workstreams. The sonic drilling and the geotechnical and hydrogeological drilling of the Phase 2 campaign are among those defined activities, and the funding is disbursed on a milestone basis subject to the conditions of the agreement.

Laboratory, QA/QC and Qualified Person Oversight

Samples will be analyzed at a commercial certified lab in Lima, yet to be defined under an ongoing bidding process. Sample preparation comprises drying at 105°C and riffle splitting to obtain a representative pulp sample of 100 grams. Analytical methods include ICP MS/OES, Atomic Absorption, Fire Assays, Sulphur and Carbon through LECO, and volumetric Fe content.

The Company will implement a QA/QC program consisting of the insertion of twin samples, coarse and pulp duplicates, certified reference materials and coarse blanks, with check assays at a second laboratory, consistent with the protocol applied to the Phase 1 program and described in the Company’s news release of April 9, 2025. Core logging, sampling and the QA/QC program are supervised by the Company’s Qualified Person, and an independent Qualified Person will carry out data verification and the MRE. The Company expects to release assay results in the next four to six weeks, after validation of each batch under the QA/QC program.

Schedule and Next Steps

The Company expects to complete the Phase 2 drilling campaign in the second quarter of 2027, with assays following the progress of drilling, and targets the first MRE for the Quiulacocha tailings in the third quarter of 2027. These expectations depend on drilling performance during the rainy season, on laboratory turnaround and on the results of the QA/QC program, and there can be no assurance that the campaign or the MRE will be completed as planned.

Qualified Person

Mr. Alfonso Palacio Castilla, Professional Member of the Institute of Materials, Minerals and Mining (MIMMM), Chartered Engineer (CEng) of the UK Engineering Council, and Senior Project Manager for CDPR, has reviewed and approved the scientific and technical information contained in this news release. Mr. Palacio is a Qualified Person for the purposes of reporting in compliance with NI 43-101. Mr. Palacio has verified the Phase 2 drilling data reported herein, consisting of drillhole locations, depths, core recovery and sample intervals, by reviewing the field logs and the drilling contractor’s daily reports against the Company’s drillhole database. No analytical results are reported in this news release.

Cautionary Note Regarding Mineral Disclosure

The Company has not established a mineral resource or mineral reserve for the Quiulacocha tailings, or for the tailings beneath the Excelsior stockpile, in accordance with NI 43-101. The Phase 2 program is designed to generate data to support the preparation of a first Mineral Resource Estimate.

About Cerro de Pasco Resources

Cerro de Pasco Resources Inc. is focused on developing its 100%-owned El Metalurgista concession in central Peru, which hosts silver-rich tailings and stockpiles accumulated over more than a century of mining in one of the most prolific polymetallic districts in the Americas. The Company’s strategy is to reprocess historic mining waste to recover value while addressing the long-term environmental liabilities associated with these tailings.

For more information, please visit www.pascoresources.com.

Further Information

Donna Yoshimatsu, VP Investor Relations
Mobile: +1 416-722-2456
Email: dyoshi@pascoresources.com

Forward-Looking Statements

Certain information contained herein may constitute “forward-looking information” under Canadian securities legislation. Generally, forward-looking information can be identified using forward-looking terminology such as “plans”, “seeks”, “expects”, “estimates”, “intends”, “anticipates”, “believes”, “could”, “might”, “likely”, “scheduled” or variations of such words or statements that certain actions, events or results “may”, “will”, “could”, “would”, “might”, “will be taken”, “occur”, “be achieved” or other similar expressions.

Forward-looking statements, including the expectations of CDPR’s management regarding the advancement, timing, scope and completion of the Phase 2 drilling campaign at the Quiulacocha TSF; the number of holes, meters and samples to be completed and the rate of advance of the drilling rigs; the timing and content of future releases of assay results; the selection of the analytical laboratory and the application of the QA/QC program; the preparation and timing of a first Mineral Resource Estimate for the Quiulacocha tailings; the evaluation and potential execution of drilling at the toe of the Excelsior stockpile, including the availability of surface access and permits; the disbursement of project development funding by DFC and the use of such funding; the preparation of the EIA and the technical studies of the Project; and the timing, outcome and impact of permitting and regulatory processes, are based on CDPR’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of CDPR to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Forward-looking information is based on the opinions, estimates and assumptions of management as of the date of this news release. These assumptions include that the drilling contractor will maintain the rate of advance achieved to date, including during the rainy season; that the drilling permits will remain in force for the period granted; that the analytical laboratory will be awarded and will deliver results within the expected turnaround; that the QA/QC program will validate the results; that DFC will disburse the project development funding on achievement of the agreed milestones; and that the Company will have the funds required to complete the campaign.

Forward-looking statements are subject to business and economic factors and uncertainties and other factors that could cause actual results to differ materially from these forward-looking statements, including weather, ground and equipment conditions affecting drilling; delays or failures in laboratory analysis or QA/QC; the risk that the data generated do not support a Mineral Resource Estimate; the risk of termination of the Transfer Contract with AMSAC, announced on October 21, 2026, if the reprocessing authorization is not obtained within one year of the application; access or permit restrictions affecting the drilling, including at the Excelsior stockpile; delays in permitting; the availability of financing, including the DFC funding; and the risk factors set out in CDPR’s public documents, available on SEDAR+ at www.sedarplus.ca. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

The Company has not established a mineral resource or mineral reserve for the Quiulacocha tailings in accordance with NI 43-101 respecting Standards of Disclosure for Mineral Projects. Ongoing drilling, assay, metallurgical and related technical work are intended to support a first Mineral Resource Estimate and future technical studies; there can be no assurance that any such estimate or study will be completed or, if completed, that it will support the advancement of the Project.

Although CDPR believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements and forward-looking information. Forward-looking information is provided as of the date of this news release. Except where required by applicable law, CDPR disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this news release.

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/c47a9460-f1f1-4f44-a44c-58865440bb52
https://www.globenewswire.com/NewsRoom/AttachmentNg/7f54af0e-eade-48b9-86cd-48bc89abb6f9
https://www.globenewswire.com/NewsRoom/AttachmentNg/b23e6ce8-14e3-45c2-8396-af6ab0fdd7dd
https://www.globenewswire.com/NewsRoom/AttachmentNg/5dc599c9-ff07-4288-9f34-502795898dcb
https://www.globenewswire.com/NewsRoom/AttachmentNg/5a5e2c2c-864c-443b-9fe4-5ddc3cb5b281

This press release was published by a CLEAR® Verified individual.

• Teva to obtain U.S. commercialization rights for two immunology biosimilars: ETICOVO^® upon close and infliximab-abda in Q3 2027
• Collaboration combines Samsung Bioepis’ biosimilar expertise with Teva’s commercial capabilities
• Agreement expands collaboration with Samsung Bioepis, strengthening Teva’s generics powerhouse and biosimilars portfolio as part of its Pivot to Growth strategy

TEL AVIV, Israel and INCHEON, South Korea, Nov. 03, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Samsung Bioepis Co., Ltd. today announced that they have entered into a license and commercialization agreement for two FDA-approved immunology biosimilars: infliximab-abda, a biosimilar to Remicade^®1 (infliximab) and ETICOVO^® (etanercept-ykro), a biosimilar to Enbrel^®2 (etanercept).

Under the terms of the agreement, Teva will obtain U.S. commercialization rights to etanercept-ykro at closing, while U.S. commercialization rights to infliximab-abda will transfer to Teva in Q3 2027. The timing of Teva’s future U.S. commercialization of etanercept-ykro will be announced at a later date. Samsung Bioepis will remain responsible for regulatory oversight and manufacturing of both products. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals, and is currently anticipated to close by the end of 2026.

“This agreement strengthens our collaboration with Samsung Bioepis and will expand our U.S. immunology portfolio with two additional biologic treatment options,” said Richard Francis, President and CEO of Teva. “Biosimilars are an important part of our Pivot to Growth strategy, helping us build a stronger portfolio while expanding access to high-quality medicines. Together, we have an opportunity to bring more treatment choices to patients living with chronic inflammatory conditions.”

“We are delighted to expand our strategic alliance with Teva to strengthen the commercial footprint of our immunology portfolio in the U.S.,” said Kyung-Ah Kim, President and Chief Executive Officer of Samsung Bioepis. “Infliximab-abda has established a proven track record of clinical efficacy and supply reliability since its launch, while ETICOVO^® represents an FDA-approved therapy poised to broaden treatment choices for patients. By pairing our dedication to high-quality biologic development and manufacturing with Teva’s commercial reach across U.S. healthcare channels, we aim to ensure uninterrupted treatment continuity for existing patients and bring sustainable value to the U.S. healthcare system.”

Under the terms of the agreement and subject to certain conditions, Teva will pay Samsung Bioepis an upfront payment over the next 3 years. Samsung Bioepis may be eligible for additional launch and sales milestones payments. Teva and Samsung Bioepis will share profit from the commercialization of these products.

The agreement builds on a series of biosimilar collaborations between Teva and Samsung Bioepis. In 2025, the companies announced a U.S. agreement for EPYSQLI^® (eculizumab-aagh), a biosimilar to Soliris^®3 (eculizumab). In 2026, the companies announced two agreements, including one for OPUVIZ^® (aflibercept) in Canada and a separate global agreement to license, develop and commercialize up to six potential biosimilar candidates currently in early-stage development, including biosimilar candidates referencing Fasenra^®4 (benralizumab) and Ilaris^®5 (canakinumab).

About Infliximab-abda and etanercept-ykro

Both biosimilars are tumor necrosis factor (TNF) inhibitors indicated for the treatment of chronic inflammatory and autoimmune conditions:

• infliximab-abda⁶ was approved by the FDA in 2017 for indications including Crohn’s disease (adult and pediatric), ulcerative colitis (adult and pediatric), rheumatoid arthritis (in combination with methotrexate), ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Teva will newly assume commercialization of the product, scheduled to take effect in the third quarter of 2027.
• etanercept-ykro⁷ was approved by the FDA in 2019 and is not currently available on the U.S. market. It is approved for indications including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis (patients aged 2 years and older), psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis (patients aged 4 years and older).

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR INFLIXIMAB-ABDA
SERIOUS INFECTIONS
Patients treated with infliximab products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Discontinue infliximab-abda if a patient develops a serious infection or sepsis.
Reported infections include:

• Active tuberculosis (TB), including reactivation of latent TB. Patients frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before infliximab-abda use and during therapy. Treatment for latent infection should be initiated prior to infliximab-abda use.
• Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, pneumocystosis, and cryptococcosis. Patients may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness.
• Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella, Listeria, and Salmonella.

The risks and benefits of treatment with infliximab-abda should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Closely monitor patients for the development of signs and symptoms of infection during and after treatment with infliximab-abda, including the possible development of TB in patients who tested negative for latent TB infection prior to initiating therapy, who are on treatment for latent TB, or who were previously treated for TB infection.
Risk of infection may be higher in patients greater than 65 years of age, pediatric patients, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressant therapy. In clinical trials, other serious infections observed in patients treated with infliximab products included pneumonia, cellulitis, abscess, and skin ulceration.

MALIGNANCIES
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including infliximab products. Approximately half of these cases were lymphomas, including Hodgkin’s and non-Hodgkin’s lymphoma. The other cases represented a variety of malignancies, including rare malignancies that are usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months after the first dose of therapy. Most of the patients were receiving concomitant immunosuppressants.
Postmarketing cases of hepatosplenic T-cell lymphoma, a rare type of T-cell lymphoma, have been reported in patients treated with TNF blockers, including infliximab products. These cases have had a very aggressive disease course and have been fatal. The majority of reported cases have occurred in patients with Crohn’s disease or ulcerative colitis and most were in adolescent and young adult males. Almost all of these patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with a TNF blocker at or prior to diagnosis. Carefully assess the risks and benefits of treatment with infliximab-abda, especially in these patient types.
In clinical trials of all TNF inhibitors, more cases of lymphoma were observed compared with controls and the expected rate in the general population. However, patients with Crohn’s disease, rheumatoid arthritis, or plaque psoriasis may be at higher risk for developing lymphoma. In clinical trials of some TNF inhibitors, including infliximab products, more cases of other malignancies were observed compared with controls. The rate of these malignancies among patients treated with infliximab products was similar to that expected in the general population whereas the rate in control patients was lower than expected. Cases of acute and chronic leukemia have been reported with postmarketing TNF-blocker use. As the potential role of TNF inhibitors in the development of malignancies is not known, caution should be exercised when considering treatment of patients with a current or a past history of malignancy or other risk factors such as chronic obstructive pulmonary disease (COPD).
Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF-blocker therapy, including infliximab products. Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.
A population-based retrospective cohort study found a 2- to 3-fold increase in the incidence of invasive cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-naïve patients or the general population, particularly those over 60 years of age. A causal relationship between infliximab products and cervical cancer cannot be excluded. Periodic screening should continue in women treated with infliximab products.

CONTRAINDICATIONS
The use of infliximab-abda at doses >5 mg/kg is contraindicated in patients with moderate or severe heart failure. infliximab-abda is contraindicated in patients with a previous severe hypersensitivity reaction to infliximab products or any of the inactive ingredients of infliximab-abda or any murine proteins (severe hypersensitivity reactions have included anaphylaxis, hypotension, and serum sickness).

WARNINGS AND PRECAUTIONS

HEPATITIS B REACTIVATION
TNF inhibitors, including infliximab products, have been associated with reactivation of hepatitis B virus (HBV) in patients who are chronic carriers. Some cases were fatal. Patients should be tested for HBV infection before initiating INFLIXIMAB-ABDA. For patients who test positive, consult a physician with expertise in the treatment of hepatitis B. Exercise caution when prescribing infliximab-abda for patients identified as carriers of HBV and monitor closely for active HBV infection during and following termination of therapy with INFLIXIMAB-ABDA. Discontinue infliximab-abda in patients who develop HBV reactivation and initiate antiviral therapy with appropriate supportive treatment. Exercise caution when considering resumption of infliximab-abda and monitor patients closely.

HEPATOTOXICITY
Severe hepatic reactions, including acute liver failure, jaundice, hepatitis, and cholestasis have been reported rarely in patients receiving infliximab products postmarketing. Some cases were fatal or required liver transplant. Aminotransferase elevations were not noted prior to discovery of liver injury in many cases. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or marked liver enzyme elevations (eg, ≥5 times the upper limit of normal) develop, infliximab-abda should be discontinued, and a thorough investigation of the abnormality should be undertaken.

HEMATOLOGIC EVENTS
Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia (some fatal) have been reported in patients using infliximab products. The causal relationship to infliximab therapy remains unclear. Exercise caution in patients who have ongoing or a history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs and symptoms of blood dyscrasias or infection. Consider discontinuation of infliximab-abda in patients who develop significant hematologic abnormalities.

HYPERSENSITIVITY
Infliximab products have been associated with hypersensitivity reactions that differ in their time of onset and required hospitalization in some cases. Most hypersensitivity reactions (including anaphylaxis, urticaria, dyspnea, and/or hypotension) have occurred during or within 2 hours of infliximab product infusion. Serious infusion reactions including anaphylaxis were infrequent. infliximab-abda should be discontinued for severe hypersensitivity reactions. Medications for the treatment of hypersensitivity reactions should be available.

CARDIOVASCULAR AND CEREBROVASCULAR REACTIONS DURING AND AFTER INFUSION
Serious cerebrovascular accidents, myocardial ischemia/infarction (some fatal), hypotension, hypertension, and arrhythmias have been reported during and within 24 hours of initiation of infliximab infusion. Cases of transient visual loss have been reported during or within 2 hours of infusion of infliximab. Monitor patients during infusion and, if a serious reaction occurs, discontinue infusion. Manage reactions according to signs and symptoms.

NEUROLOGIC EVENTS
TNF inhibitors, including infliximab products, have been associated in rare cases with central nervous system (CNS) manifestation of systemic vasculitis, seizure, and new onset or exacerbation of CNS demyelinating disorders, including multiple sclerosis and optic neuritis, and peripheral demyelinating disorders, including Guillain-Barré syndrome. Exercise caution when considering infliximab-abda in patients with these disorders and consider discontinuation if these disorders develop.

AUTOIMMUNITY
Treatment with infliximab products may result in the formation of autoantibodies and, rarely, in development of a lupus-like syndrome. Discontinue treatment if symptoms of a lupus-like syndrome develop.

DRUG INTERACTIONS

USE WITH OTHER DRUGS
Concurrent use of infliximab-abda with other biological products used to treat the same conditions as infliximab-abda is not recommended because of the possibility of an increased risk of infection. Care should be taken when switching from one biologic to another, since overlapping biological activity may further increase the risk of infection.

VACCINATIONS AND USE OF LIVE VACCINES/THERAPEUTIC INFECTIOUS AGENTS
Prior to initiating infliximab-abda in pediatric and adult patients, update vaccinations in accordance with current vaccination guidelines. Live vaccines or therapeutic infectious agents should not be given with infliximab-abda due to the possibility of clinical infections, including disseminated infections.
At least a 6-month waiting period following birth is recommended before the administration of any live vaccine to infants exposed in utero to infliximab products.

ADVERSE REACTIONS
In clinical trials, the most common adverse reactions occurring in >10% of patients included infections (e.g., upper respiratory, sinusitis, and pharyngitis), infusion-related reactions, headache, and abdominal pain.

INDICATIONS
Infliximab-abda is a TNF blocker indicated for: 
Crohn’s Disease

• Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease (CD) who have had an inadequate response to conventional therapy.
• Infliximab-abda is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing Crohn’s disease.

Pediatric Crohn’s Disease

• Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age or older with moderately to severely active Crohn’s disease (CD) who have had an inadequate response to conventional therapy.

Ulcerative Colitis

• Infliximab-abda is indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Pediatric Ulcerative Colitis

• Infliximab-abda is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

Rheumatoid Arthritis

• Infliximab-abda is indicated, in combination with methotrexate (MTX), for reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis (RA).

Ankylosing Spondylitis

• Infliximab-abda is indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS).

Psoriatic Arthritis

• Infliximab-abda is indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients with psoriatic arthritis (PsA).

Plaque Psoriasis

• Infliximab-abda is indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis (Ps) who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. Infliximab-abda should only be administered to patients who will be closely monitored and have regular follow-up visits with a physician.

Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.

IMPORTANT SAFETY INFORMATION AND INDICATIONS FOR ETICOVO (etanercept-ykro)
SERIOUS INFECTIONS
Patients treated with etanercept products are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ETICOVO should not be initiated in the presence of sepsis, active infections, or allergy to ETICOVO or its components. ETICOVO should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Test patients for latent TB before ETICOVO use and periodically during therapy. Initiate treatment for latent infection prior to ETICOVO use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric antifungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.
The risks and benefits of treatment with ETICOVO should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Monitor patients closely for the development of signs and symptoms of infection during and after treatment with ETICOVO, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy.

MALIGNANCIES
Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including etanercept products.
In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA patients. The role of TNF blocker therapy in the development of malignancies is unknown.
Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population.
Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including etanercept products. Periodic skin examinations should be considered for all patients at increased risk for skin cancer.
Pediatric Patients
In patients who initiated therapy at ≤18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin’s and non-Hodgkin’s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants.

CONTRAINDICATIONS
ETICOVO is contraindicated in patients with sepsis.

WARNINGS AND PRECAUTIONS

NEUROLOGIC REACTIONS
Treatment with TNF-blocking agents, including etanercept products, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ETICOVO therapy. Prescribers should exercise caution in considering the use of ETICOVO in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders.

NEW ONSET OR WORSENING OF HEART FAILURE
Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking etanercept products. Caution should be used when using ETICOVO in patients with CHF. These patients should be carefully monitored.

HEMATOLOGIC REACTIONS
Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to etanercept products therapy remains unclear. Exercise caution when considering ETICOVO in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ETICOVO if significant hematologic abnormalities are confirmed.

HEPATITIS B REACTIVATION
Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including etanercept products. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ETICOVO in these patients.

ALLERGIC REACTIONS
Allergic reactions associated with administration of ETICOVO during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, discontinue administration of ETICOVO and initiate appropriate therapy immediately.

IMMUNIZATIONS
Avoid concurrent administration of live vaccines with ETICOVO. Patients, if possible, should be brought up to date with all immunizations prior to initiating ETICOVO. In patients with exposure to varicella virus, temporarily discontinue ETICOVO and consider prophylactic treatment with Varicella Zoster Immune Globulin.

AUTOIMMUNITY
Autoantibodies may develop with ETICOVO, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ETICOVO. Stop ETICOVO if findings suggestive of lupus-like syndrome or autoimmune hepatitis develop and evaluate the patient.

NOT RECOMMENDED FOR GRANULOMATOSIS WITH POLYANGIITIS PATIENTS ON IMMUNOSUPPRESSANTS
The use of ETICOVO in patients with granulomatosis with polyangiitis receiving immunosuppressive agents (e.g., cyclophosphamide) is not recommended.

INCREASED MORTALITY IN PATIENTS WITH MODERATE TO SEVERE ALCOHOLIC HEPATITIS
Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ETICOVO in patients with moderate to severe alcoholic hepatitis.

DRUG INTERACTIONS
The use of ETICOVO in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ETICOVO and anakinra is not recommended. Hypoglycemia has been reported following initiation of ETICOVO therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients.

ADVERSE REACTIONS
The most commonly reported adverse reactions in RA clinical trials were injection site reaction and infection. In clinical trials of all other adult indications, adverse reactions were similar to those reported in RA clinical trials.
In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population.

INDICATIONS
ETICOVO^® (etanercept-ykro) is a TNF blocker indicated for: 

• Rheumatoid Arthritis: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA).
• Polyarticular Juvenile Idiopathic Arthritis (pJIA): Reducing signs and symptoms of moderately to severely active pJIA in patients 2 years of age and older. 
• Psoriatic Arthritis: Reducing signs and symptoms, inhibiting structural damage progression, and improving physical function in adults (alone or with methotrexate). 
• Ankylosing Spondylitis: Reducing signs and symptoms in patients with active disease. 
• Plaque Psoriasis: Treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

Please read the Full Prescribing Information, including BOXED WARNINGS and Medication Guide.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit https://www.tevapharm.com.

Teva Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully execute the agreement with Samsung Bioepis and to successfully commercialize infliximab-abda and ETICOVO^® (etanercept-ykro) in the U.S.; our ability to successfully execute our additional collaborations with Samsung Bioepis; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generic medicines; and other factors discussed in our Quarterly Reports on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ending December 31, 2025, including in the section captioned “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world’s leading biopharmaceutical company. As a wholly owned subsidiary of Samsung Epis Holdings (KRX: 0126Z0), Samsung Bioepis continues to advance a broad pipeline of biologic candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology, nephrology, neurology, and endocrinology. For more information, please visit www.samsungbioepis.com and follow us on LinkedIn and X.

Media Contacts

Teva Media Inquiries:

TevaCommunicationsNorthAmerica@tevapharm.com

Teva Investor Relations Inquiries:

TevaIR@tevapharm.com

Samsung Bioepis Media Inquiries:

Anna Nayun Kim, nayun86.kim@samsung.com

Yoon Kim, yoon1.kim@samsung.com

________________________________

¹ Remicade^® is a trademark of Janssen Biotech, Inc., a Johnson & Johnson company
² Enbrel^® is a trademark of Immunex Corporation, an Amgen subsidiary.
³ Soliris^® is a trademark of Alexion Pharmaceuticals, Inc.
⁴ Fasenra^® is a trademark of AstraZeneca AB.
⁵ Ilaris^® is a trademark of Novartis AG.
⁶ infliximab-abda – FDA-approved biosimilar to Remicade^® (infliximab): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761054
⁷ etanercept-ykro – FDA-approved biosimilar to Enbrel^® (etanercept): https://purplebooksearch.fda.gov/index.cfm?event=productdetails&blaNo=761066